{
    "nctId": "NCT02640053",
    "briefTitle": "Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome",
    "officialTitle": "Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Area Under the Curve (AUC) EORTC CIPN20 Sensory Neuropathy Subscale Adjusting for Baseline",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to complete questionnaires by themselves or with assistance\n* Planned paclitaxel at a dose of 80 mg/m\\^2 intravenously (I.V.) given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (NOTE: trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for poly adenosine diphosphate ribose polymerase \\[PARP\\] inhibitors), at the entering Academic and Community Cancer Research United (ACCRU) institution\n* Life expectancy \\> 6 months\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Patient has score of 0 or 1 on the neurotoxicity evaluation, as determined by the healthcare provider\n\nExclusion Criteria:\n\n* Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause\n* Diagnosis of fibromyalgia\n* Any prior exposure to neurotoxic chemotherapy\n* History of Raynaud?s disease, cryoglobulinemia",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}